Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977921> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4308977921 endingPage "vii94" @default.
- W4308977921 startingPage "vii94" @default.
- W4308977921 abstract "Abstract Local intracranial drug delivery for high-grade glioma has been developed over the last two decades with chemotherapeutic agents administered immediately adjuvant to neurosurgery to overcome poor blood brain barrier permeability. In addition to this, the incorporation of nanoparticles (NPs) into local drug delivery systems (DDS) can result in increased penetration of chemotherapeutics through brain parenchyma, transporting the drug further from the administration site than by drug molecule diffusion alone.Here we adopted two model local DDS containing NPs to compare the depth of penetration through brain parenchyma. Approach one consisted of a thermosensitive in situ assembling polymer matrix loaded with polymer-doxorubicin conjugated NPs which can line the resection cavity walls, while approach two consisted of drug-loaded (etoposide and olaparib) poly(lactic acid)-poly(ethylene glycol) polymeric NPs held within a bioadhesive pectin hydrogel and delivered via a spray device.We assessed the efficacy of both DDS at preventing recurrence of high-grade glioma in an orthotopic rat 9L gliosarcoma model following surgical resection. In addition to monitoring long-term survival, the effect of each DDS was measured histologically by H&E and by caspase-1 (inflammatory response) and ki67 (cell proliferation) immunostaining staining. Depth of drug penetration was evaluated on post-sacrificial sections using Orbitrap-Secondary Ion Mass Spectroscopy (OrbiSIMS) and fluorescent microscopy. In vivo data suggests that the delivery mechanism of the NPs affects the efficacy of the DDS, whereby long-term survival was observed in rats treated with the sprayed olaparib/etoposide NP formulation, relative to rats where olaparib/etoposide was simply pipetted into the resection cavity. OrbiSIMS confirmed the presence of doxorubicin, olaparib and etoposide in brain tissue. Our work encourages consideration of mass spectrometry modalities to complement in vivo efficacy studies, as an analytical tool to assess brain distribution of systemically administered drugs, or localised brain penetration of drugs released biomaterial-based DDS." @default.
- W4308977921 created "2022-11-20" @default.
- W4308977921 creator A5001987906 @default.
- W4308977921 creator A5010860660 @default.
- W4308977921 creator A5019725924 @default.
- W4308977921 creator A5023915285 @default.
- W4308977921 creator A5029836300 @default.
- W4308977921 creator A5040828807 @default.
- W4308977921 creator A5059878597 @default.
- W4308977921 creator A5066593009 @default.
- W4308977921 date "2022-11-01" @default.
- W4308977921 modified "2023-10-18" @default.
- W4308977921 title "DDEL-03. ASSESSING THE DEPTH OF DRUG PENETRATION INTO BRAIN PARENCHYMA FROM LOCAL DRUG DELIVERY SYSTEMS IN AN ORTHOTOPIC HIGH GRADE GLIOMA ALLOGRAFT USING ORBITRAP-SECONDARY ION MASS SPECTROMETRY" @default.
- W4308977921 doi "https://doi.org/10.1093/neuonc/noac209.349" @default.
- W4308977921 hasPublicationYear "2022" @default.
- W4308977921 type Work @default.
- W4308977921 citedByCount "0" @default.
- W4308977921 crossrefType "journal-article" @default.
- W4308977921 hasAuthorship W4308977921A5001987906 @default.
- W4308977921 hasAuthorship W4308977921A5010860660 @default.
- W4308977921 hasAuthorship W4308977921A5019725924 @default.
- W4308977921 hasAuthorship W4308977921A5023915285 @default.
- W4308977921 hasAuthorship W4308977921A5029836300 @default.
- W4308977921 hasAuthorship W4308977921A5040828807 @default.
- W4308977921 hasAuthorship W4308977921A5059878597 @default.
- W4308977921 hasAuthorship W4308977921A5066593009 @default.
- W4308977921 hasBestOaLocation W43089779211 @default.
- W4308977921 hasConcept C136229726 @default.
- W4308977921 hasConcept C155672457 @default.
- W4308977921 hasConcept C171250308 @default.
- W4308977921 hasConcept C178790620 @default.
- W4308977921 hasConcept C185592680 @default.
- W4308977921 hasConcept C192562407 @default.
- W4308977921 hasConcept C2778227246 @default.
- W4308977921 hasConcept C2779820397 @default.
- W4308977921 hasConcept C2780165375 @default.
- W4308977921 hasConcept C502942594 @default.
- W4308977921 hasConcept C71924100 @default.
- W4308977921 hasConcept C98274493 @default.
- W4308977921 hasConceptScore W4308977921C136229726 @default.
- W4308977921 hasConceptScore W4308977921C155672457 @default.
- W4308977921 hasConceptScore W4308977921C171250308 @default.
- W4308977921 hasConceptScore W4308977921C178790620 @default.
- W4308977921 hasConceptScore W4308977921C185592680 @default.
- W4308977921 hasConceptScore W4308977921C192562407 @default.
- W4308977921 hasConceptScore W4308977921C2778227246 @default.
- W4308977921 hasConceptScore W4308977921C2779820397 @default.
- W4308977921 hasConceptScore W4308977921C2780165375 @default.
- W4308977921 hasConceptScore W4308977921C502942594 @default.
- W4308977921 hasConceptScore W4308977921C71924100 @default.
- W4308977921 hasConceptScore W4308977921C98274493 @default.
- W4308977921 hasIssue "Supplement_7" @default.
- W4308977921 hasLocation W43089779211 @default.
- W4308977921 hasOpenAccess W4308977921 @default.
- W4308977921 hasPrimaryLocation W43089779211 @default.
- W4308977921 hasRelatedWork W2016699102 @default.
- W4308977921 hasRelatedWork W2318502166 @default.
- W4308977921 hasRelatedWork W2396320787 @default.
- W4308977921 hasRelatedWork W2748952813 @default.
- W4308977921 hasRelatedWork W2804446591 @default.
- W4308977921 hasRelatedWork W2899084033 @default.
- W4308977921 hasRelatedWork W2982021042 @default.
- W4308977921 hasRelatedWork W3003056427 @default.
- W4308977921 hasRelatedWork W3122005761 @default.
- W4308977921 hasRelatedWork W3163350643 @default.
- W4308977921 hasVolume "24" @default.
- W4308977921 isParatext "false" @default.
- W4308977921 isRetracted "false" @default.
- W4308977921 workType "article" @default.